home / stock / dawn / dawn articles
First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF ...
BRISBANE, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a clinical-stage biop...
BRISBANE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a clinical-stage biop...
PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN...
STAMFORD, Conn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One"...
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today&rsqu...
Although U.S. stocks closed lower on Friday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence ...
News, Short Squeeze, Breakout and More Instantly...
Day One Biopharmaceuticals Inc. Company Name:
DAWN Stock Symbol:
NASDAQ Market:
Day One Biopharmaceuticals Inc. Website:
2024-07-10 18:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 09:30:06 ET Piper Sandler analyst issues OVERWEIGHT recommendation for DAWN on July 8, 2024 07:54AM ET. The previous analyst recommendation was Overweight. DAWN was trading at $13.71 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Day One receives exclusive license for development and commercialization of MTX-13 (DAY301), which received IND clearance by the FDA in April 2024 Targets PTK7, highly expressed in broad range of adult and pediatric solid tumors BRISBANE, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- ...